0001493152-24-006815.txt : 20240215 0001493152-24-006815.hdr.sgml : 20240215 20240215080531 ACCESSION NUMBER: 0001493152-24-006815 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240215 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 24642185 BUSINESS ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 BUSINESS PHONE: (866) 594-5999 MAIL ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm
false 0000315545 0000315545 2024-02-15 2024-02-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 15, 2024

 

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

 

Delaware   001-36457   90-0031917
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

800 S. Gay Street, Suite 1610, Knoxville, TN 37929

(Address of Principal Executive Offices) (Zip Code)

 

(866) 594-5999

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01.Regulation FD Disclosure.

 

On February 15, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing it will host a conference call on February 22, 2024 at 3 p.m. EST to provide Company updates. The conference call may be accessed by registering in advance via the link provided in the Press Release or by dialing 1-800-319-4610 (in the U.S.) or 1-604-638-5340 (outside the U.S.). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

This information and the information contained in Exhibit 99.1 are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number

  

Description

     
99.1   Press Release, dated February 15, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 15, 2024

 

  PROVECTUS BIOPHARMACEUTICALS, INC.
                                          
  By: /s/ Heather Raines
    Heather Raines
    Chief Financial Officer (Principal Financial Officer)

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 


 

Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call

 

KNOXVILLE, TN, February 15, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.

 

The conference call may be accessed by registering in advance or dialing 1-800-319-4610 (in the U.S.) or 1-604-638-5340 (outside the U.S.). Please dial in approximately five minutes prior to the start of the call.

 

About Provectus

 

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

 

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

 

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.

 

FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

 

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

 

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

 

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

 

●The Company’s Annual Report on Form 10-K for the period ended December 31, 2022, and

 

●Provectus’s Quarterly Report on Form 10-Q for the period ended September 30, 2023.

 

#####

 

Contact:

Provectus Biopharmaceuticals, Inc.

Heather Raines, CPA

Chief Financial Officer

Phone: (866) 594-5999

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 pvct-20240215.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pvct-20240215_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pvct-20240215_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 15, 2024
Entity File Number 001-36457
Entity Registrant Name PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key 0000315545
Entity Tax Identification Number 90-0031917
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 800 S. Gay Street
Entity Address, Address Line Two Suite 1610
Entity Address, City or Town Knoxville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37929
City Area Code (866)
Local Phone Number 594-5999
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://provectusbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pvct-20240215.xsd pvct-20240215_lab.xml pvct-20240215_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PVCT", "nsuri": "http://provectusbio.com/20240215", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pvct-20240215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pvct-20240215_lab.xml" ] }, "presentationLink": { "local": [ "pvct-20240215_pre.xml" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "report": { "R1": { "role": "http://provectusbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://provectusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-006815-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-006815-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0000315545 2024-02-15 2024-02-15 iso4217:USD shares iso4217:USD shares false 0000315545 8-K 2024-02-15 PROVECTUS BIOPHARMACEUTICALS, INC. DE 001-36457 90-0031917 800 S. Gay Street Suite 1610 Knoxville TN 37929 (866) 594-5999 false false false false false